Alnylam Pharmaceuticals (NASDAQ:ALNY) Cut to “Hold” at StockNews.com

StockNews.com lowered shares of Alnylam Pharmaceuticals (NASDAQ:ALNY) from a buy rating to a hold rating in a research note published on Thursday.

Several other equities research analysts have also recently issued reports on the company. Cantor Fitzgerald reissued a “neutral” rating and set a $220.00 target price on shares of Alnylam Pharmaceuticals in a research note on Friday, October 11th. William Blair restated an “outperform” rating on shares of Alnylam Pharmaceuticals in a report on Tuesday, November 19th. Barclays increased their target price on shares of Alnylam Pharmaceuticals from $295.00 to $329.00 and gave the stock an “overweight” rating in a research note on Friday, November 1st. TD Cowen boosted their price target on shares of Alnylam Pharmaceuticals from $282.00 to $371.00 and gave the company a “buy” rating in a research note on Monday, October 21st. Finally, Raymond James increased their price objective on shares of Alnylam Pharmaceuticals from $275.00 to $298.00 and gave the stock an “outperform” rating in a research report on Friday, November 1st. One analyst has rated the stock with a sell rating, six have issued a hold rating and nineteen have given a buy rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $298.61.

Alnylam Pharmaceuticals Stock Up 1.9 %

NASDAQ ALNY opened at $240.55 on Thursday. The business’s fifty day simple moving average is $249.60 and its 200-day simple moving average is $259.41. The company has a quick ratio of 2.69, a current ratio of 2.75 and a debt-to-equity ratio of 31.64. The firm has a market cap of $31.03 billion, a PE ratio of -91.81 and a beta of 0.34. Alnylam Pharmaceuticals has a 52 week low of $141.98 and a 52 week high of $304.39.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last posted its earnings results on Thursday, October 31st. The biopharmaceutical company reported ($0.87) earnings per share for the quarter, missing the consensus estimate of ($0.51) by ($0.36). The business had revenue of $500.90 million for the quarter, compared to the consensus estimate of $532.91 million. Alnylam Pharmaceuticals’s revenue was down 33.3% compared to the same quarter last year. During the same quarter last year, the firm earned $1.15 EPS. As a group, equities analysts anticipate that Alnylam Pharmaceuticals will post -2.21 earnings per share for the current year.

Insider Buying and Selling at Alnylam Pharmaceuticals

In related news, EVP Tolga Tanguler sold 1,469 shares of Alnylam Pharmaceuticals stock in a transaction on Tuesday, November 26th. The shares were sold at an average price of $250.98, for a total transaction of $368,689.62. Following the sale, the executive vice president now directly owns 13,191 shares in the company, valued at $3,310,677.18. This trade represents a 10.02 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Yvonne Greenstreet sold 5,219 shares of the business’s stock in a transaction on Tuesday, November 26th. The shares were sold at an average price of $250.98, for a total transaction of $1,309,864.62. Following the completion of the sale, the chief executive officer now directly owns 78,880 shares of the company’s stock, valued at approximately $19,797,302.40. This trade represents a 6.21 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 10,122 shares of company stock worth $2,540,455 over the last ninety days. Corporate insiders own 1.50% of the company’s stock.

Institutional Trading of Alnylam Pharmaceuticals

Hedge funds and other institutional investors have recently made changes to their positions in the company. Ashton Thomas Private Wealth LLC acquired a new stake in shares of Alnylam Pharmaceuticals in the 2nd quarter valued at about $26,000. Huntington National Bank boosted its holdings in shares of Alnylam Pharmaceuticals by 91.8% in the third quarter. Huntington National Bank now owns 94 shares of the biopharmaceutical company’s stock valued at $26,000 after acquiring an additional 45 shares during the period. Hollencrest Capital Management purchased a new position in shares of Alnylam Pharmaceuticals during the third quarter worth approximately $29,000. Washington Trust Advisors Inc. acquired a new position in shares of Alnylam Pharmaceuticals in the 3rd quarter valued at $42,000. Finally, True Wealth Design LLC raised its position in Alnylam Pharmaceuticals by 15,300.0% in the 3rd quarter. True Wealth Design LLC now owns 154 shares of the biopharmaceutical company’s stock valued at $42,000 after purchasing an additional 153 shares during the last quarter. Institutional investors and hedge funds own 92.97% of the company’s stock.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.